Compare Envista Holdings Corp. with Similar Stocks
Dashboard
Poor Management Efficiency with a low ROCE of 6.67%
- The company has been able to generate a Return on Capital Employed (avg) of 6.67% signifying low profitability per unit of total capital (equity and debt)
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 5.77
Poor long term growth as Net Sales has grown by an annual rate of 2.21% over the last 5 years
Negative results in Jun 25
With ROCE of 4.03%, it has a risky valuation with a 1.04 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
USD 4,056 Million (Small Cap)
73.00
NA
0.00%
0.11
1.05%
1.31
Total Returns (Price + Dividend) 
Envista Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Envista Holdings Corp. Experiences Evaluation Revision Amidst Mixed Financial Metrics
Envista Holdings Corp. has recently adjusted its valuation, with its stock price slightly increasing. Over the past year, the company has experienced a stock return of 7.05%, lagging behind the S&P 500. Key financial metrics reveal a mixed valuation landscape compared to industry peers, indicating diverse financial health within the sector.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 94 Schemes (71.72%)
Held by 150 Foreign Institutions (16.34%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 10.57% vs -5.51% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 46.67% vs 1,400.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -2.18% vs -0.10% in Dec 2023
YoY Growth in year ended Dec 2024 is -1,016.37% vs -142.10% in Dec 2023






